Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serono and NovImmune enter antibody deal
Serono will pay a license fee of $5 million for the two the antibodies, NI-0401 and NI-0501, which are believed to have therapeutic potential in a broad range
Serono will pay a license fee of $5 million for the two the antibodies, NI-0401 and NI-0501, which are believed to have therapeutic potential in a broad range
In this study, MVA-MUC1-IL2 was administered simultaneously with cisplatin and vinorelbine in 44 stage IIIB/IV patients with non-small cell lung cancer (NSCLC). The chemo-immunotherapy regimen achieved a tumor
The randomized multinational open-label study enrolled 224 patients and the primary endpoint was overall survival. In the trial Orathecin (rubitecan) was administered at 1.5mg/m2 orally five days/week. 5-FU
Fenofibrate tablets are the AB-rated generic equivalent of Abbott’s Tricor tablets, which are indicated for the treatment of hypercholesterolemia and hypertriglyceridemia. The FDA approval follows a ruling at
Trizivir (abacavir sulfate, lamivudine, and zidovudine) is a fixed-dose-combination tablet containing the three nucleoside reverse transcriptase inhibitors Epivir (lamivudine, 3TC), Retrovir (zidovudine, ZDV) and Ziagen (abacavir sulfate, ABC).
According to results from a new phase III study, patients with moderate to severely active Crohn’s disease treated with Humira (adalimumab) saw continuing improvements in clinical response and
The study, presented at the 41st annual meeting of the American Society of Clinical Oncology (ASCO), compared the two combinations as first- or second-line treatment in patients with
Corautus’ cardiac therapy, which is considered regenerative medicine, seeks to treat the underlying causes of severe coronary artery disease through direct injection of VEGF-2 (vascular endothelial growth factor
The results also showed a decrease in the levels of tumor marker CA 19-9 in patients who received TNFerade. In addition, the maximum tolerated dose (MTD) established during
Results from two phase III trials, named ACT1 and ACT2, reveal that, among patients with moderate to severe active ulcerative colitis (UC) who experienced an inadequate response to